<p>Neurogene Inc.（納斯達克代碼：NGNE - 獲取免費報告）的股票被目前覆蓋該股票的九家評級公司一致推薦為 “適度買入”，Marketbeat Ratings 報告稱。一位股票研究分析師給予該股票賣出評級，兩位給予持有評級，六位給予買入評級。在過去一年中，發佈報告的分析師對該股票的平均 12 個月目標價為 46.1667 美元。</p>
<ul>
<li>Neurogene 股票暴跌 44%：這家生物科技公司還有希望嗎？</li>
</ul>
<p>多家研究公司對 NGNE 進行了評論。Craig Hallum 於 6 月 17 日星期二開始對 Neurogene 的股票進行覆蓋。他們對該股票設定了 “買入” 評級和 50.00 美元的目標價。Weiss Ratings 在週三的研究報告中重申了對 Neurogene 股票的 “賣出（d-）” 評級。最後，HC Wainwright 在週四的報告中重申了 “買入” 評級，並對 Neurogene 股票設定了 45.00 美元的目標價。</p>
<p><strong>閲讀我們關於 NGNE 的最新研究報告</strong></p>
<h2>Neurogene 的機構交易</h2>
<p>對沖基金和其他機構投資者最近對該公司的持倉進行了調整。Nuveen LLC 在第一季度購買了 Neurogene 股票的新股份，價值約 322,000 美元。Wellington Management Group LLP 在第一季度將其在 Neurogene 的持股增加了 58.5%。Wellington Management Group LLP 現在擁有 34,421 股該公司的股票，價值 403,000 美元，此前在上個季度又購買了 12,704 股。GAMMA Investing LLC 在第一季度將其在 Neurogene 的持股增加了 2,985.1%。GAMMA Investing LLC 現在擁有 4,134 股該公司的股票，價值 48,000 美元，此前在此期間又收購了 4,000 股。紐約梅隆銀行在第一季度將其在 Neurogene 的持股增加了 8.2%。紐約梅隆銀行現在擁有 24,445 股該公司的股票，價值 286,000 美元，此前在此期間又收購了 1,844 股。最後，EntryPoint Capital LLC 在第一季度收購了 Neurogene 的新股份，價值約 148,000 美元。目前 52.37% 的股票由機構投資者持有。</p>
<h2>Neurogene 股票下跌 4.3%</h2>
<p>週五，NGNE 股票開盤價為 30.21 美元。Neurogene 的 52 周低點為 6.88 美元，52 周高點為 74.49 美元。該公司的市值為 4.311 億美元，市盈率為-7.01，貝塔值為 1.58。該公司的 50 日移動平均線為 20.09 美元，200 日移動平均線為 18.02 美元。</p>
<p>Neurogene（納斯達克代碼：NGNE - 獲取免費報告）最近於 8 月 11 日星期一發布了季度財報。該公司報告季度每股收益為（1.05 美元），超出分析師一致預期的（1.15 美元）0.10 美元。平均而言，股票研究分析師預測 Neurogene 本年度每股收益為-4.27 美元。</p>
<h2>Neurogene 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Neurogene Inc 是一家生物技術公司，開發用於罕見神經疾病的基因治療藥物。該公司的產品候選包括 NGN-401，該藥物包裝在腺病毒 9 中，目前正在進行 Rett 綜合症的 1/2 期臨牀試驗；以及 NGN-101，一種常規基因治療候選藥物，目前正在進行 CLN5 Batten 病的 1/2 期臨牀試驗。</p>
<h2>精選文章</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Neurogene</li>
<li>最佳能源股票 - 現在值得購買的能源股票</li>
<li>3 只 heavily shorted 股票，可能在降息時上漲</li>
<li>10 月值得考慮購買的 3 只股票</li>
<li>博通獲得第二個 420 美元目標價，CPO 勝利提升前景</li>
<li>什麼是二次公開募股？投資者需要知道什麼</li>
<li>百事可樂的深度折扣即將消失：趁現在買入</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkdORQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkdORQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 Neurogene 嗎？</h2>
<p>在你考慮 Neurogene 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 Neurogene 並不在名單上。</p>
<p>雖然 Neurogene 目前在分析師中被評為適度買入，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

NGNE

<p>Neurogene Inc.（納斯達克代碼：NGNE）獲得了九位分析師的共識推薦評級為 “適度買入”。該股票有一項賣出評級、兩項持有評級和六項買入評級，平均目標價格為 46.17 美元。最近的交易中，股價下跌了 4.3%，開盤價為 30.21 美元。公司報告的季度每股收益為（1.05 美元），超出預期。機構投資者持有該股票的 52.37%，其中 Nuveen 和 Wellington Management 等公司的持倉顯著增加。Neurogene 專注於針對罕見神經疾病的基因治療，正在進行其產品候選者的臨牀試驗</p>

<p>Shares of Neurogene Inc. (NASDAQ:NGNE - Get Free Report) have been assigned a consensus recommendation of &#34;Moderate Buy&#34; from the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $46.1667.</p>
<div class="lb-trans"><p>Neurogene Inc.（納斯達克代碼：NGNE - 獲取免費報告）的股票被目前覆蓋該股票的九家評級公司一致推薦為 “適度買入”，Marketbeat Ratings 報告稱。一位股票研究分析師給予該股票賣出評級，兩位給予持有評級，六位給予買入評級。在過去一年中，發佈報告的分析師對該股票的平均 12 個月目標價為 46.1667 美元。</p>
</div><ul>
<li>Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?&#34;</li>
</ul>
<div class="lb-trans"><ul>
<li>Neurogene 股票暴跌 44%：這家生物科技公司還有希望嗎？</li>
</ul>
</div><p>A number of research firms have commented on NGNE. Craig Hallum began coverage on shares of Neurogene in a research report on Tuesday, June 17th. They set a &#34;buy&#34; rating and a $50.00 price target on the stock. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Neurogene in a research report on Wednesday. Finally, HC Wainwright reiterated a &#34;buy&#34; rating and issued a $45.00 target price on shares of Neurogene in a report on Thursday.</p>
<div class="lb-trans"><p>多家研究公司對 NGNE 進行了評論。Craig Hallum 於 6 月 17 日星期二開始對 Neurogene 的股票進行覆蓋。他們對該股票設定了 “買入” 評級和 50.00 美元的目標價。Weiss Ratings 在週三的研究報告中重申了對 Neurogene 股票的 “賣出（d-）” 評級。最後，HC Wainwright 在週四的報告中重申了 “買入” 評級，並對 Neurogene 股票設定了 45.00 美元的目標價。</p>
</div><p><strong>Read Our Latest Research Report on NGNE</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 NGNE 的最新研究報告</strong></p>
</div><h2>Institutional Trading of Neurogene</h2>
<div class="lb-trans"><h2>Neurogene 的機構交易</h2>
</div><p>Hedge funds and other institutional investors have recently made changes to their positions in the business. Nuveen LLC bought a new stake in shares of Neurogene in the 1st quarter worth approximately $322,000. Wellington Management Group LLP raised its holdings in shares of Neurogene by 58.5% in the 1st quarter. Wellington Management Group LLP now owns 34,421 shares of the company's stock worth $403,000 after purchasing an additional 12,704 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Neurogene by 2,985.1% during the first quarter. GAMMA Investing LLC now owns 4,134 shares of the company's stock valued at $48,000 after acquiring an additional 4,000 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Neurogene by 8.2% during the first quarter. Bank of New York Mellon Corp now owns 24,445 shares of the company's stock valued at $286,000 after acquiring an additional 1,844 shares during the period. Finally, EntryPoint Capital LLC acquired a new stake in shares of Neurogene during the first quarter valued at approximately $148,000. 52.37% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>對沖基金和其他機構投資者最近對該公司的持倉進行了調整。Nuveen LLC 在第一季度購買了 Neurogene 股票的新股份，價值約 322,000 美元。Wellington Management Group LLP 在第一季度將其在 Neurogene 的持股增加了 58.5%。Wellington Management Group LLP 現在擁有 34,421 股該公司的股票，價值 403,000 美元，此前在上個季度又購買了 12,704 股。GAMMA Investing LLC 在第一季度將其在 Neurogene 的持股增加了 2,985.1%。GAMMA Investing LLC 現在擁有 4,134 股該公司的股票，價值 48,000 美元，此前在此期間又收購了 4,000 股。紐約梅隆銀行在第一季度將其在 Neurogene 的持股增加了 8.2%。紐約梅隆銀行現在擁有 24,445 股該公司的股票，價值 286,000 美元，此前在此期間又收購了 1,844 股。最後，EntryPoint Capital LLC 在第一季度收購了 Neurogene 的新股份，價值約 148,000 美元。目前 52.37% 的股票由機構投資者持有。</p>
</div><h2>Neurogene Trading Down 4.3%</h2>
<div class="lb-trans"><h2>Neurogene 股票下跌 4.3%</h2>
</div><p>NGNE stock opened at $30.21 on Friday. Neurogene has a 52 week low of $6.88 and a 52 week high of $74.49. The company has a market capitalization of $431.10 million, a price-to-earnings ratio of -7.01 and a beta of 1.58. The firm's 50-day moving average is $20.09 and its two-hundred day moving average is $18.02.</p>
<div class="lb-trans"><p>週五，NGNE 股票開盤價為 30.21 美元。Neurogene 的 52 周低點為 6.88 美元，52 周高點為 74.49 美元。該公司的市值為 4.311 億美元，市盈率為-7.01，貝塔值為 1.58。該公司的 50 日移動平均線為 20.09 美元，200 日移動平均線為 18.02 美元。</p>
</div><p>Neurogene (NASDAQ:NGNE - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($1.05) EPS for the quarter, topping analysts' consensus estimates of ($1.15) by $0.10. On average, equities research analysts predict that Neurogene will post -4.27 earnings per share for the current year.</p>
<div class="lb-trans"><p>Neurogene（納斯達克代碼：NGNE - 獲取免費報告）最近於 8 月 11 日星期一發布了季度財報。該公司報告季度每股收益為（1.05 美元），超出分析師一致預期的（1.15 美元）0.10 美元。平均而言，股票研究分析師預測 Neurogene 本年度每股收益為-4.27 美元。</p>
</div><h2>Neurogene Company Profile</h2>
<div class="lb-trans"><h2>Neurogene 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.</p>
<div class="lb-trans"><p>Neurogene Inc 是一家生物技術公司，開發用於罕見神經疾病的基因治療藥物。該公司的產品候選包括 NGN-401，該藥物包裝在腺病毒 9 中，目前正在進行 Rett 綜合症的 1/2 期臨牀試驗；以及 NGN-101，一種常規基因治療候選藥物，目前正在進行 CLN5 Batten 病的 1/2 期臨牀試驗。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Neurogene</li>
<li>Best Energy Stocks - Energy Stocks to Buy Now</li>
<li>3 Heavily Shorted Stocks That Could Pop on Rate Cuts</li>
<li>3 Stocks to Consider Buying in October</li>
<li>Broadcom Gets Second $420 Target as CPO Win Boosts Outlook</li>
<li>What is a Secondary Public Offering? What Investors Need to Know</li>
<li>PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Neurogene</li>
<li>最佳能源股票 - 現在值得購買的能源股票</li>
<li>3 只 heavily shorted 股票，可能在降息時上漲</li>
<li>10 月值得考慮購買的 3 只股票</li>
<li>博通獲得第二個 420 美元目標價，CPO 勝利提升前景</li>
<li>什麼是二次公開募股？投資者需要知道什麼</li>
<li>百事可樂的深度折扣即將消失：趁現在買入</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkdORQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=NGNE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Neurogene Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Neurogene 嗎？</h2>
</div><p>Before you consider Neurogene, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Neurogene 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurogene wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦，現在就買入，以便在更廣泛的市場注意到之前……而 Neurogene 並不在名單上。</p>
</div><p>While Neurogene currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Neurogene 目前在分析師中被評為適度買入，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Neurogene Inc.（NASDAQ:NGNE）被分析師平均推薦為 “適度買入”